Finch Therapeutics
Biotechnology, 200 Inner Belt Rd Ste 400, Somerville, Massachusetts, 02143, United States, 11-50 Employees
Phone Number: 61********
Who is FINCH THERAPEUTICS
Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2...
Read More
-
Headquarters: 200 Inner Belt Rd Ste 400, Somerville, Massachusetts, 02143, United States
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
Industry: Biotechnology
SIC Code: 87
|
NAICS Code: 54 |
Show More
Does something look wrong? Fix it. | View contact records from FINCH THERAPEUTICS
Finch Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Finch Therapeutics
Answer: Finch Therapeutics's headquarters are located at 200 Inner Belt Rd Ste 400, Somerville, Massachusetts, 02143, United States
Answer: Finch Therapeutics's phone number is 61********
Answer: Finch Therapeutics's official website is https://finchtherapeutics.com
Answer: Finch Therapeutics's revenue is $10 Million to $25 Million
Answer: Finch Therapeutics's SIC: 87
Answer: Finch Therapeutics's NAICS: 54
Answer: Finch Therapeutics has 11-50 employees
Answer: Finch Therapeutics is in Biotechnology
Answer: Finch Therapeutics contact info: Phone number: 61******** Website: https://finchtherapeutics.com
Answer: Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). Additionally, Finch has pre-clinical assets that are designed to target ulcerative colitis, Crohns disease, and autism spectrum disorder. Finch has a robust intellectual property estate reflecting the Companys pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent CDI and focus on realizing the value of its intellectual property estate and other assets.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month